167 related articles for article (PubMed ID: 38575707)
21. Interplay between EZH2 and G9a Regulates CXCL10 Gene Repression in Idiopathic Pulmonary Fibrosis.
Coward WR; Brand OJ; Pasini A; Jenkins G; Knox AJ; Pang L
Am J Respir Cell Mol Biol; 2018 Apr; 58(4):449-460. PubMed ID: 29053336
[TBL] [Abstract][Full Text] [Related]
22. Chromatin remodeling by the histone methyltransferase EZH2 drives lung pre-malignancy and is a target for cancer prevention.
Tellez CS; Picchi MA; Juri D; Do K; Desai DH; Amin SG; Hutt JA; Filipczak PT; Belinsky SA
Clin Epigenetics; 2021 Feb; 13(1):44. PubMed ID: 33632299
[TBL] [Abstract][Full Text] [Related]
23. Fibroblast Growth Factor Receptor Inhibitors Reduce Adipogenesis of Orbital Fibroblasts and Enhance Myofibroblastic Differentiation in Graves' Orbitopathy.
Shih SR; Liao SL; Shih CW; Wei YH; Lu TX; Chou CH; Yen EY; Chang YC; Lin CC; Chi YC; Yang WS; Tsai FC
Ocul Immunol Inflamm; 2021 Jan; 29(1):193-202. PubMed ID: 31657648
[No Abstract] [Full Text] [Related]
24. The Potential Role of Osteopontin in the Pathogenesis of Graves' Ophthalmopathy.
Lou H; Wu LQ; Wang H; Wei RL; Cheng JW
Invest Ophthalmol Vis Sci; 2021 Sep; 62(12):18. PubMed ID: 34546326
[TBL] [Abstract][Full Text] [Related]
25. Autologous T-lymphocytes stimulate proliferation of orbital fibroblasts derived from patients with Graves' ophthalmopathy.
Feldon SE; Park DJ; O'Loughlin CW; Nguyen VT; Landskroner-Eiger S; Chang D; Thatcher TH; Phipps RP
Invest Ophthalmol Vis Sci; 2005 Nov; 46(11):3913-21. PubMed ID: 16249464
[TBL] [Abstract][Full Text] [Related]
26. The Role of Adipsin, Complement Factor D, in the Pathogenesis of Graves' Orbitopathy.
Byeon HJ; Chae MK; Ko J; Lee EJ; Kikkawa DO; Jang SY; Yoon JS
Invest Ophthalmol Vis Sci; 2023 Aug; 64(11):13. PubMed ID: 37555734
[TBL] [Abstract][Full Text] [Related]
27. Blockade of enhancer of zeste homolog 2 alleviates renal injury associated with hyperuricemia.
Shi Y; Xu L; Tao M; Fang L; Lu J; Gu H; Ma S; Lin T; Wang Y; Bao W; Qiu A; Zhuang S; Liu N
Am J Physiol Renal Physiol; 2019 Mar; 316(3):F488-F505. PubMed ID: 30566000
[TBL] [Abstract][Full Text] [Related]
28. Yes-Associated Protein Mediates the Transition from Inflammation to Fibrosis in Graves' Orbitopathy.
Ko J; Kim YJ; Choi SH; Lee CS; Yoon JS
Thyroid; 2023 Dec; 33(12):1465-1475. PubMed ID: 37800725
[No Abstract] [Full Text] [Related]
29. A central role for G9a and EZH2 in the epigenetic silencing of cyclooxygenase-2 in idiopathic pulmonary fibrosis.
Coward WR; Feghali-Bostwick CA; Jenkins G; Knox AJ; Pang L
FASEB J; 2014 Jul; 28(7):3183-96. PubMed ID: 24652950
[TBL] [Abstract][Full Text] [Related]
30. Molecular biomarkers of Graves' ophthalmopathy.
Longo CM; Higgins PJ
Exp Mol Pathol; 2019 Feb; 106():1-6. PubMed ID: 30414981
[TBL] [Abstract][Full Text] [Related]
31. Chemokine Expression during Adipogenesis and Inflammation in Orbital Fibroblasts from Patients with Graves' Orbitopathy.
Lee CE; Choi SH; Yoon JS
Korean J Ophthalmol; 2020 Jun; 34(3):192-202. PubMed ID: 32495527
[TBL] [Abstract][Full Text] [Related]
32. Role of Proprotein Convertase Subtilisin/Kexin Type 9 in the Pathogenesis of Graves' Orbitopathy in Orbital Fibroblasts.
Lee GE; Kim J; Lee JS; Ko J; Lee EJ; Yoon JS
Front Endocrinol (Lausanne); 2020; 11():607144. PubMed ID: 33488522
[TBL] [Abstract][Full Text] [Related]
33. Essential role of connective tissue growth factor (CTGF) in transforming growth factor-β1 (TGF-β1)-induced myofibroblast transdifferentiation from Graves' orbital fibroblasts.
Tsai CC; Wu SB; Kau HC; Wei YH
Sci Rep; 2018 May; 8(1):7276. PubMed ID: 29739987
[TBL] [Abstract][Full Text] [Related]
34. Histamine induces NF-κB controlled cytokine secretion by orbital fibroblasts via histamine receptor type-1.
Virakul S; Phetsuksiri T; van Holten-Neelen C; Schrijver B; van Steensel L; Dalm VASH; Paridaens D; van den Bosch WA; van Hagen PM; Dik WA
Exp Eye Res; 2016 Jun; 147():85-93. PubMed ID: 27170049
[TBL] [Abstract][Full Text] [Related]
35. Cell density-dependent stimulation of PAI-1 and hyaluronan synthesis by TGF-β in orbital fibroblasts.
Galgoczi E; Jeney F; Gazdag A; Erdei A; Katko M; Nagy DM; Ujhelyi B; Steiber Z; Gyory F; Berta E; Nagy EV
J Endocrinol; 2016 May; 229(2):187-96. PubMed ID: 26979769
[TBL] [Abstract][Full Text] [Related]
36. Potential Therapeutic Role of Bone Morphogenic Protein 7 (BMP7) in the Pathogenesis of Graves' Orbitopathy.
Kim BY; Choi SH; Kim JY; Ko J; Yook JI; Kim HS; Lee EJ; Kikkawa DO; Yoon JS
Invest Ophthalmol Vis Sci; 2022 Jun; 63(6):7. PubMed ID: 35671049
[TBL] [Abstract][Full Text] [Related]
37. Therapeutic effect of ibrutinib, a selective Bruton's tyrosine kinase inhibitor, in orbital fibroblasts from patients with Graves' orbitopathy.
Park HY; Chae MK; Ko J; Kikkawa DO; Jang SY; Yoon JS
PLoS One; 2022; 17(12):e0279060. PubMed ID: 36521376
[TBL] [Abstract][Full Text] [Related]
38. Astragaloside IV attenuates orbital inflammation in Graves' orbitopathy through suppression of autophagy.
Li H; Zhang Y; Min J; Gao L; Zhang R; Yang Y
Inflamm Res; 2018 Feb; 67(2):117-127. PubMed ID: 29127443
[TBL] [Abstract][Full Text] [Related]
39. Evidence for enhanced Thy-1 (CD90) expression in orbital fibroblasts of patients with Graves' ophthalmopathy.
Khoo TK; Coenen MJ; Schiefer AR; Kumar S; Bahn RS
Thyroid; 2008 Dec; 18(12):1291-6. PubMed ID: 18976167
[TBL] [Abstract][Full Text] [Related]
40. Role of microRNA-146a in regulation of fibrosis in orbital fibroblasts from patients with Graves' orbitopathy.
Jang SY; Park SJ; Chae MK; Lee JH; Lee EJ; Yoon JS
Br J Ophthalmol; 2018 Mar; 102(3):407-414. PubMed ID: 29101123
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
